Roselt, P.
27  Ergebnisse:
Personensuche X
?
1

P2.01-01 Initial Result of the ImmunoPET Phase1 Study: Char..:

Hegi-Johnson, F. ; Rudd, S. ; Roselt, P....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S295 , 2023
 
?
2

PD-0970 Biodistribution Data of ImmunoPET: A Phase 0/1 Stud..:

Hegi-Johnson, F. ; Rudd, S. ; Roselt, P....
Radiotherapy and Oncology.  182 (2023)  - p. S817-S818 , 2023
 
?
3

P2.03-01 Initial Biodistribution Data of ImmunoPET A Phase ..:

Hegi-Johnson, F. ; Rudd, S. ; Callahan, J....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S131-S132 , 2022
 
?
4

MA09.05 Increased PD-L1 Tracer Uptake in Recently-irradiate..:

Hegi-Johnson, F. ; Akhurst, T. ; Rudd, S....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S75-S76 , 2022
 
?
5

P1.10-02 ImmunoPET: A Phase 0/1 Study Characterising PD-L1 ..:

MacManus, M. ; Rudd, S. ; Roselt, P....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S107-S108 , 2022
 
?
6

Enhancing PET signal at target tissue in vivo: dendritic hy..:

Ma, M. ; Imberti, C. ; Cullinane, C....
Nuclear Medicine and Biology.  72-73 (2019)  - p. S12 , 2019
 
?
7

ORIGINAL ARTICLE: Pilot comparison of 18F‐fluorocholine and..:

Beauregard, J‐M ; Williams, SG ; DeGrado, TR..
Journal of Medical Imaging and Radiation Oncology.  54 (2010)  4 - p. 325-332 , 2010
 
?
 
?
10

A novel approach using 123I-iodophenyl pentadecanoic acid (..:

Unger, S. A. ; Barnden, L. R. ; Roselt, P. U...
Nuclear Medicine Communications.  20 (1999)  4 - p. 378 , 1999
 
1-15